| |
|
|
| Vol. 24, #4 • Monday, January 23, 2023 |
|
| |
|
Off the Cuff: Gratitude and Legacies
This weekend I am attending the Rising Stars Reception being held at the Global Specialty Lens Symposium in Las Vegas. This reception is held by the GP Lens Institute to recognize practitioners at the forefront of their specialty.
Dr. Stephanie Woo, who won GPLI's Naomi "Jo" Svochak GP Practitioner of the Year award in 2022, emailed me soon after Dr. Epstein passed, wanting to create a new award in his name. She conceived of and donated proceeds from two Woo Universities to initiate this award in his memory. Many others also donated via Dr. Epstein's memorial webpage or directly via the GPLI website.
Even though he spent the latter part of his career on dry eye and ocular surface disease, Dr. Epstein got his start in specialty lens fitting. It’s very gratifying to see practitioners recognizing his contributions years after it was his primary focus. I extend a big thank you to Dr. Woo for creating the award, Dr. Ed Bennett, president of the GPLI for sponsoring it, and to everyone who donated to keep Dr. Epstein's legacy within our profession alive.
Want to share your perspective?
Write to Dr. Shannon L. Steinhäuser, OD, MS, FAAO at ssteinhauser@gmail.com.
The views expressed in this editorial are solely those of the author and do not necessarily represent the opinions of Jobson Medical Information LLC (JMI), or any other entities or individuals.
|
|
|
|
|
| |
| |
|
The Use of Progressive Addition Lenses to Improve the Daily Visual Function of Children Receiving Topical Atropine Treatment
These authors presented the changes in visual function when progressive addition lenses
(PAL) are added in children using topical atropine as a myopia control therapy. Daily
visual complaints and the determination of their near correction were studied. Forty children aged 7 to 12 years were recruited. Distance and near visual acuity, accommodative lag, heterophoria, near point of convergence and stereopsis were examined, and a questionnaire of daily visual complaints was administered.
Significant differences in visual functions were found after the near correction was prescribed. Significant improvements in distance and near visual acuity, lag of accommodation and binocular visual function were observed, and fewer visual complaints were reported at the Harmon distance.
The authors concluded that the use of PAL is helpful for children undergoing topical
atropine treatment for myopia control, particularly those receiving medium to high
doses. This combination therapy could also be applied to younger children who have a
low tolerance to contact lenses, with less risk of ocular adverse effects.
SOURCE: Sun HY, Tsai JD, Nien YS, et al. The use of progressive addition lenses to improve the daily visual function of children receiving topical atropine treatment. Ophthalmic Physiol Opt. 2022 Dec 1. [Epub ahead of print].
|
|
|
|
|
|
|
| |
| |
|
High Load of Demodex in Young Children With Chalazia
This case-control prospective study, conducted at Children’s Hospital of Fudan
University between December 2018 and January 2019, investigated the correlation
between demodicosis and pediatric chalazia. One hundred one consecutive pediatric
patients with chalazia and 42 pediatric patients without chalazia underwent eyelash
sampling and Demodex examination using light microscopy, and mite presence and
counts were documented.
The Demodex count and prevalence of the chalazia group was much higher than that of
the control group. The Demodex count and prevalence of the multiple chalazia subgroup was much higher than that of the single chalazion subgroup. The Demodex count and prevalence of the chalazia with skin erosion subgroup was much higher than that of the without skin erosion subgroup. After adjustment for age and gender, Demodex count, but not presence, was significantly correlated with chalazia.
These results demonstrated that Demodex mites were more prevalent and quantitative
in children with chalazia, and children with severe chalazia had higher Demodex prevalence and quantity. High Demodex count rather than presence was associated with chalazia.
SOURCE: Xiao Y, Gao L, Shen L, et al. High load of demodex in young children with chalazia. J Pediatr Ophthalmol Strabismus. 2022 Nov 28:1-7.
|
|
|
|
Impact of Intraoperative Floppy Iris Syndrome in Cataract Surgery By Phacoemulsification: Analysis of 622 Cases
Small pupil syndromes, including intraoperative floppy iris syndrome (IFIS), increase the risk of complications during cataract surgery if proper surgical planning is not performed. Tamsulosin is associated with a very significant increase in the risk of IFIS, due to the prolonged inactivation of alpha-1 adrenergic receptors in the smooth muscle fiber of the iris. This single-center prospective observational study included 622 eyes of 502 patients, of which 337 were women.
The mean age of the sample was 74.8 years. Sixty-one cases of IFIS (11%) were observed, of which 13 received treatment with Tamsulosin and 1 with Doxazosin. Twenty-three cases of IFIS were observed in female patients. The female:male ratio was approximately 1:3. 19 cases (3%) of severe IFIS were observed, of which 6 received treatment with alpha-antagonists, with no statistically significant correlation. The mean surgical time was 13.80 minutes (standard deviation [SD]: 4.01 minutes) in patients without IFIS and 16.93 min (SD: 4.32 minutes) in patients with IFIS. The relationship between the duration of the surgical procedure in minutes and the presence of IFIS was statistically significant.
The authors concluded that, regardless of the degree of severity, the diagnosis of IFIS
lengthened the surgical time in cataract surgery. They wrote, this represents yet another piece of
evidence that supports the use of less selective alpha-1 adrenergic antagonist
treatments than Tamsulosin or the performance of cataract surgery before starting
these treatments.
SOURCE: Herranz Cabarcos A, Pifarré Benítez R, Martínez Palmer A. Impact of intraoperative floppy IRIS syndrome in cataract surgery by phacoemulsification: Analysis of 622 cases. Arch Soc Esp Oftalmol (Engl Ed). 2022 Nov 8. [Epub ahead of print].
|
|
|
|
|
|
|
|
|
Industry News
Bausch & Lomb Rolls Out New Ocular Vitamin Formula, Acquires AcuFocus
Bausch + Lomb announced the U.S. introduction of PreserVision AREDS 2 Formula mini soft gels with OCUSorb. The company says the product offers a proprietary composition of lutein and zeaxanthin, and that its “OCUSorb” formulation has been “clinically shown to provide superior absorption of these nutrients into the body as compared to the original PreserVision AREDS 2 mini soft gel formula.” Read more.
In addition, Bausch + Lomb and AcuFocus announced that an affiliate of Bausch + Lomb acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. AcuFocus offers the IC-8 Apthera intraocular lens, which was approved by the FDA in July 2022 as the first and only small aperture non-toric extended depth of focus IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time. Read more.
Essilor is Official Distributor for Espansione Group
Essilor Instruments announced it is the official distributor for the North American market of Espansione Group’s full portfolio of solutions and future innovations. Espansione Group focuses on ophthalmic and dermatological solutions to treat a number of conditions via patented, certified and light-based technologies such as Light Modulation Low-level Light Therapy (LM LLLT) photobiomodulation technology and Optimal Power Energy Intense Pulsed Light (OPE IPL) Learn more about the company.
|
|
|
|
Journal Reviews Editor:
Katherine M. Mastrota, MS, OD, EMBA, FAAO
|
|
|
Optometric Physician™ (OP) newsletter is owned and published by Dr. Arthur Epstein. It is distributed by the Review Group, a Division of Jobson Medical Information LLC (JMI), 19 Campus Boulevard, Newtown Square, PA 19073.
To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.
To ensure delivery, please be sure to add Optometricphysician@jobsonmail.com to your address book or safe senders list.
Click here if you do not want to receive future emails from Optometric Physician.
HOW TO SUBMIT NEWS
E-mail optometricphysician@jobson.com or FAX your news to: 610.492.1039.
Advertising: For information on advertising in this e-mail newsletter, please contact sales managers Michael Hoster, Michele Barrett or Jonathan Dardine.
News: To submit news or contact the editor, send an e-mail, or FAX your news to 610.492.1039
|
|
|
|
|
|
|
|
|
